BRCA2 hereditary breast cancer pathophenotype

Breast Cancer Research and Treatment

Volumn 44, Issue 3, 1997, Pages 275-277

  Marcus, Joseph N ^a   Watson, Patrice ^b   Page, David L ^c   Narod, Steven A ^d   Tonin, Patricia ^e   Lenoir, Gilbert M ^f   Serova, Olga ^f   Lynch, Henry T ^b  

^a ST LUKE S HOSPITAL   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

BCRA1; BCRA2; DNA cytometry; Familial breast cancer; Hereditary breast cancer; Pathology; Tubular lobular group

Indexed keywords

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; FAMILIAL CANCER; FEMALE; GENE MUTATION; HUMAN; INVASIVE CARCINOMA; PHENOTYPE; PRIORITY JOURNAL;

BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENETIC MARKERS; HUMANS; MUTATION; NEOPLASM PROTEINS; PHENOTYPE; TRANSCRIPTION FACTORS;

EID: 0030789568     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005830230664     Document Type: Article

References (14)

1. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT: Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77: 697-709, 1996
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Magnion J, Collins N, Gregory S, Gumbs C, Michlem G, Tarfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop DP, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR: Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789-792, 1995
3. Fisher ER, Gregorio RM, Redmond C, Fisher B: Tubulo-lobular invasive breast cancer: A variant of lobular invasive cancer. Human Pathol 8: 679-683, 1977
4. Stalsberg H, Thomas DB, Noonan EA: The WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Histologic types of breast carcinoma in relation to international variation and breast cancer risk factors. Int J Cancer 44: 399-409, 1989
5. Marcus JN, Watson P, Page DL, Lynch HT: The pathology and heredity of breast cancer in younger women. J Natl Cancer Inst (Monogr) 16: 23-34, 1994
6. Borg A, Zhang Q-X, Johannsson O, Olsson H: High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas. J Natl Cancer Inst 86: 792-794, 1994
7. McDivitt RW, Hutter RVP, Foote FW, Stewart FW: In situ lobular carcinoma. A prospective follow-up study indicating cumulative patient risks. JAMA 201: 96-100, 1967
8. Haagensen CD, Lane N, Lattes R, Bodian C: Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 42: 737-769, 1978
9. Page DL, Kidd TE, Dupont WD, Simpson JF, Rogers LW: Lobular neoplasia of the breast: Higher risk for subsequent invasive cancer predicted by more extensive disease. Human Pathol 22: 1232-1239, 1991
10. Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW: Infiltrating lobular carcinoma of the breast. Histopathol 6: 149-161, 1982
11. Narod SA, Ford D, Devilee P, Barkadottir RB, Lynch HT, Smith SA et al.: An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 56: 254-264, 1995
12. Lynch H, Marcus JN, Watson P, Page D: Distinctive clinicopathologic features of BRCA1-linked hereditary breast cancer. Proc Am Soc Clin Oncol 13: 56, 1994
13. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, Vincent-Salomon A, Jaquemier J, Birnbaum D, Sobol H: Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56: 471-474, 1996
14. Sigurdsson H, Agnarsson BA, Jonasson JG, Bjornsdottir IB, Barkardottir RB, Gudlaugsdottir S, Egilsson V: Worse survival among breast cancer patients in families carrying the BRCA2 susceptibility gene. Breast Cancer Res Treat 37 (Suppl): 33, 1996